

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



November 28, 2024

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Regulatory Order

This is to inform that the Company has received orders passed by statutory authority. Relevant details, as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in **Annexure A**.

The Company shall take appropriate action in the matter.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
a)	Name of the authority	Regional Director, North Western Region, Ministry of Corporate Affairs
b)	Nature and details of the action(s) taken, initiated, or order(s) passed	Orders passed in the matter of application of compounding of offences under Section 441 for alleged violations under Section 129 and Section 188 of the Companies Act, 2013 and a total combined compounding fee is levied on certain past and present directors/officers of the company viz. Mr. Dilip Shanghvi INR 9,50,000, Mr. Sudhir Valia INR 9,00,000, Mr. Sailesh Desai INR 9,00,000, Mr. K. Subramanian INR 1,50,000, Mr. Uday Baldota INR 6,00,000, and Mr. C. Muralidharan INR 1,50,000.
c)	Date of receipt of direction or order, including any ad-interim or interim orders or any other communication from the authority	November 27, 2024
d)	Details of the violation(s)/contravention(s) Committed or alleged to be committed	<p>This matter pertains to the earlier investigation carried out by SEBI, in which a Settlement was reached with SEBI in February 2021 without admission or denial of guilt; however, on the same matter, the Ministry of Corporate Affairs also initiated an investigation in parallel in 2019.</p> <p>In continuation to the intimation dated October 11, 2024, these additional orders pertain to the application of compounding of offences for alleged violation under Section 129 and Section 188 for non-disclosure of certain transactions with related parties in the Board's Report and financial statements for the financial years ranging from 2015-16 to 2018-19; and not obtaining approval of the Board/ shareholders for a related party transaction with Aditya Medisales Limited for the financial years 2014-15 to 2017-18.</p> <p>For the subsequent periods, the related party transactions have been duly disclosed in the Board's Reports/financial statements, and necessary approvals have been obtained.</p>
e)	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financial, operation or other activities.